<DOC>
	<DOCNO>NCT01082328</DOCNO>
	<brief_summary>The primary objective study evaluate proportion responder ( , great equal [ &gt; = ] 30 percent reduction Baseline blood phenylalanine [ Phe ] level ) treatment Kuvan® ( sapropterin dihydrochloride ) 20 milligram per kilogram per day ( mg/kg/day ) 28 day .</brief_summary>
	<brief_title>Response Kuvan® Subjects With Phenylketonuria ( PKU ) 4 Weeks Testing Period</brief_title>
	<detailed_description />
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Subjects age 4 year old time inform consent obtain Subjects diagnose PKU ( subgroup define : classic PKU [ blood Phe great { &gt; } 1200 micromole per liter { mcmol/L } ] , mild PKU [ blood Phe 600 to1200 mcmol/L ] mild hyperphenylalaninemia ( HPA ) [ blood Phe 300 600 mcmol/L ] Subjects receive previous treatment sapropterin dihydrochloride ( either Kuvan® formulation tetrahydrobiopterin [ BH4 ] ) Subjects adherent normal diet willing adhere give diet 4 week study period Subjects provide sign ( parent 18 year ) write informed consent Subjects document genotyping phenylalanine hydroxylase ( PAH ) mutation ( PKU genotype ) Phenylketonuria ( PKU ) diagnosis document least two historical blood Phe level 400 mcmol/L Female subject childbearing potential ( , appropriate , male subject female partner childbearing potential ) must willing avoid pregnancy use adequate method contraception ( define two barrier method one barrier method spermicide , intrauterine device use oral female contraceptive ) 4 week prior , 12 week last dose trial medication Women childbearing potential ( purpose trial , woman childbearing potential define `` All female subject puberty unless postmenopausal least 2 year , surgically sterile sexually inactive '' ) must negative urine pregnancy test Baseline visit Subjects document BH4 deficiency Subjects contraindication receive Kuvan® outline summary product characteristic ( SmPC ) willing able comply study procedure Subjects pregnant , plan pregnancy breastfeed Subjects expose investigational medicinal drug treatment within 30 day 5 halflives , whichever longer , prior Screening visit Subjects use concomitant treatment folate synthesis inhibit drug Subjects concurrent use Levodopa Subjects concurrent use inhibitor dihydrofolate reductase ( example , methotrexate , trimethoprim ) Subjects concurrent use agent cause vasodilation , include administer topically , affect nitric oxide ( NO ) metabolism action include classical NO donor ( example , glyceryl trinitrate ( GTN ) , isosorbide dinitrate ( ISDN ) , sodium nitroprusside ( SNP ) , molsidomin ) , phosphodiesterase type 5 ( PDE5 ) inhibitor minoxidil Subjects concurrent disease potentially interfere safety ( example , seizure disorder , oral steroid dependent asthma , condition require systemic corticosteroid , insulindependent diabetes mellitus ) Subjects inadequate liver function , define alanine aminotransferase ( ALT ) &gt; = 2 time upper limit normal ( ULN ) Subjects clinically significant renal dysfunction , define serum creatinine &gt; 250 mcmol/L Have medical condition , judgment investigator , would jeopardize subject 's safety follow exposure study drug would significantly interfere subject 's ability comply provision protocol</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Phenylketonuria ( PKU )</keyword>
	<keyword>Hyperphenylalaninemia ( HPA )</keyword>
	<keyword>Kuvan®</keyword>
	<keyword>Sapropterin dihydrochloride</keyword>
	<keyword>Kuvan responder</keyword>
	<keyword>Tetrahydrobiopterin ( BH4 )</keyword>
</DOC>